Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.
Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, Takeuchi M, Ichikawa W, Fujii M. Tsuji A, et al. Among authors: matsuoka h. Target Oncol. 2021 Nov;16(6):753-760. doi: 10.1007/s11523-021-00845-y. Epub 2021 Oct 31. Target Oncol. 2021. PMID: 34718946 Review.
[HAI chemotherapy for liver metastases of colorectal cancer].
Matsuoka H, Maeda K, Hanai T, Sato H, Masumori K, Koide Y, Katsuno H, Agata T, Noro T, Honda K, Shiota M, Ozeki S, Hatta K, Morise Z, Sugioka A, Ota H. Matsuoka H, et al. Gan To Kagaku Ryoho. 2010 Jul;37(7):1303-6. Gan To Kagaku Ryoho. 2010. PMID: 20647714 Japanese.
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Takahashi T, et al. Among authors: matsuoka h. Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2. Int J Clin Oncol. 2013. PMID: 22383023 Clinical Trial.
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: matsuoka h. Ann Surg Oncol. 2017 Feb;24(2):546-553. doi: 10.1245/s10434-016-5557-9. Epub 2016 Sep 8. Ann Surg Oncol. 2017. PMID: 27638675 Clinical Trial.
Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: matsuoka h. Ann Surg Oncol. 2016 Dec;23(Suppl 5):1064. doi: 10.1245/s10434-016-5593-5. Ann Surg Oncol. 2016. PMID: 27646021 No abstract available.
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Xu RH, et al. Among authors: matsuoka h. Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. Lancet Oncol. 2018. PMID: 29555258 Clinical Trial.
Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study.
Matsuoka H, Morise Z, Tanaka C, Hayashi T, Ikeda Y, Maeda K, Masumori K, Koide Y, Katsuno H, Tanahashi Y, Nakajima S, Hanai T, Kato Y, Sugioka A, Uyama I. Matsuoka H, et al. World J Surg Oncol. 2019 Feb 15;17(1):33. doi: 10.1186/s12957-019-1575-y. World J Surg Oncol. 2019. PMID: 30770753 Free PMC article.
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. Taniguchi H, et al. Among authors: matsuoka h. Transl Oncol. 2020 Jul;13(7):100786. doi: 10.1016/j.tranon.2020.100786. Epub 2020 May 16. Transl Oncol. 2020. PMID: 32428838 Free PMC article.
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Iwasa S, Muro K, Morita S, Park YS, Nakamura M, Kotaka M, Nishina T, Matsuoka H, Ahn JB, Lee KW, Hong YS, Han SW, Cho SH, Zhang DS, Fang WJ, Bai L, Yuan XL, Yuan Y, Yamada Y, Sakamoto J, Kim TW. Iwasa S, et al. Among authors: matsuoka h. Cancer Sci. 2021 Nov;112(11):4669-4678. doi: 10.1111/cas.15092. Epub 2021 Aug 31. Cancer Sci. 2021. PMID: 34327766 Free PMC article. Clinical Trial.
2,233 results